Association of Sporadic and Genetic Parkinson's Disease with Cancer: Insights from the PPMI Cohort.

Abstract read

In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Evangelos Sfikas1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece.ORCID 0000-0003-2655-1145

Christos Koros1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece.

Funding

Michael J. Fox Foundation PPMI2

6 · The paper itself

Abstract

BACKGROUND/

objectivesPrior studies have reported a complex interplay between Parkinson's disease (PD) and malignancy. Although patients with PD often present a lower general risk for several types of cancer, some forms-including melanoma-show elevated frequency. The present work aimed to evaluate the occurrence of cancers other than melanoma among individuals with sporadic and genetic PD.

methodsWe examined medical histories from 1888 participants with PD and 438 healthy controls (HCs) using the Parkinson's Progression Markers Initiative (PPMI) dataset, with a focus on neoplastic disease. In cases with positive cancer history, genetic information was additionally assessed [carriers of mutations in the most prevalent PD-related genes were evaluated].

resultsOur results demonstrate that cancer incidence was antecedent to PD diagnosis for the majority of PD patients, while the most common cancer types apart from malignant melanoma were non-melanoma skin cancer and prostate cancer.

conclusionsRegarding genetic PD patients, the most common cancer types in the

Indexed as

NeoplasmsParkinson DiseaseAgedCase-Control StudiesCohort StudiesFemaleGenetic Predisposition to DiseaseGlucosylceramidaseHumansIncidenceLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedMutationUbiquitin-Protein LigasesGBA protein, humanGlucosylceramidaseLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanparkin proteinUbiquitin-Protein Ligasesalpha-synucleincancergeneticglucocerebrosidaseneoplasmParkinson’s disease

Identifiers

PMID41300754

DOI10.3390/genes16111302

PMCPMC12651979

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.